Get notified of page updates

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

Advanced endometrial cancer

Clinicaltrials.gov identifier:
NCT04463771
PRINTER FRIENDLY PAGE
Overview
Who Can Join
Glossary on
off

About the Study

This study is no longer enrolling patients. 

 

This study is for people with advanced or endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of ) alone or in combination with other immunotherapies or targeted therapies.

 

This Study is Open To:

This study is no longer enrolling patients. 

This Study is NOT Open To:

This study is no longer enrolling patients. 

Advanced endometrial cancer

Clinicaltrials.gov identifier:
NCT04463771
PRINTER FRIENDLY PAGE